San Diego, CA, United States of America

Randolph D Christen


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1993-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Randolph D Christen

Introduction

Randolph D Christen is a notable inventor based in San Diego, CA. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Christen's work focuses on enhancing the efficacy of cancer therapies.

Latest Patents

Christen's latest patents include groundbreaking methods for treating cancer. One patent involves the use of Taxol and epidermal growth factor to sensitize various types of cancer cells to cytotoxic agents. This invention provides a method to treat cancer and other cell proliferative diseases by administering a sensitizing agent prior to or concurrently with a cytotoxic agent. Another patent focuses on enhancing the efficacy of anti-neoplastic drugs using epidermal growth factor. This method also aims to augment the sensitivity of cancer cells to cisplatin and other cytotoxic agents, offering new avenues for cancer treatment.

Career Highlights

Randolph D Christen is affiliated with the University of California, where he continues to advance research in cancer therapies. His work has been instrumental in developing methods that improve treatment outcomes for patients suffering from various forms of cancer.

Collaborations

Christen has collaborated with esteemed colleagues such as Stephen B Howell and Seiji Isonishi. These partnerships have further enriched his research and contributed to the development of innovative cancer treatment methods.

Conclusion

Randolph D Christen's contributions to cancer treatment through his patents demonstrate his commitment to improving patient outcomes. His innovative approaches continue to pave the way for advancements in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…